Zhan Q, Xu JH, Yu YY, Lo KK E, Felicianna, El-Nezami H, Zeng Z. Human immune repertoire in hepatitis B virus infection. World J Gastroenterol 2021; 27(25): 3790-3801 [PMID: 34321844 DOI: 10.3748/wjg.v27.i25.3790]
Corresponding Author of This Article
Zheng Zeng, MD, PhD, Chief Physician, Department of Infectious Diseases, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. zeng@bjmu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Qiao Zhan, Jing-Hang Xu, Yan-Yan Yu, Zheng Zeng, Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China
Emily Lo KK, Felicianna, Hani El-Nezami, School of Biological Sciences, University of Hong Kong, Hong Kong, China
Hani El-Nezami, Institute of Public Health and Clinical Nutrition, School of Medicine, University of Eastern Finland, Kuopio FI-70211, Finland
Author contributions: Zhan Q and Xu JH wrote the paper; Yu YY, Lo KK E, Felicianna collected the data; El-Nezami H and Zeng Z revised the paper. Zhan Q and Xu JH equally contributed to the manuscript.
Supported byThe National Natural Science Foundation of China, No. 61972007 and No. 30671855; the International Science & Technology Cooperation Program of China, No. 2014DFR31200; and Ministry of Science and Technology of China, No. 2017ZX10202202.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng Zeng, MD, PhD, Chief Physician, Department of Infectious Diseases, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. zeng@bjmu.edu.cn
Received: January 25, 2021 Peer-review started: January 25, 2021 First decision: February 27, 2021 Revised: March 8, 2021 Accepted: May 27, 2021 Article in press: May 27, 2021 Published online: July 7, 2021 Processing time: 161 Days and 12.9 Hours
Abstract
Hepatitis B virus (HBV) infection is a public health threat that affects 257 million people worldwide and can progress to liver cirrhosis, liver failure, and hepatocellular carcinoma. The HBV antigen- induced adaptive immune response plays an important role in HBV clearance. Immune repertoire sequencing (IRS) has been used to investigate the molecular mechanisms behind the immune system, find novel ways to treat HBV infection, and evaluate the genetic responses and immune characteristics of individuals infected by HBV or immunized by HBV vaccine. This review summarizes the human immune repertoire analysis methodology, and the application of the IRS in the prediction of HBV infection progression, treatment, and vaccination.
Core Tip: A Hepatitis B virus (HBV) cure depends on activation of the anti-HBV adaptive immune system. Immune repertoire sequencing is a novel method to investigate all aspects of the human adaptive immune system. However, the immune repertoire in HBV infection is still not clear. We review the immune repertoire analysis methodology and provide a new insight into outcomes of HBV infection and vaccination.
